Seelos Therapeutics Inc (SEEL)
0.29
-0.03
(-8.29%)
USD |
NASDAQ |
May 07, 14:01
Seelos Therapeutics Enterprise Value: 15.54M for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 15.54M |
| May 03, 2024 | 15.86M |
| May 02, 2024 | 15.73M |
| May 01, 2024 | 15.32M |
| April 30, 2024 | 15.03M |
| April 29, 2024 | 15.05M |
| April 26, 2024 | 15.20M |
| April 25, 2024 | 15.12M |
| April 24, 2024 | 15.33M |
| April 23, 2024 | 15.69M |
| April 22, 2024 | 15.67M |
| April 19, 2024 | 15.79M |
| April 18, 2024 | 15.84M |
| April 17, 2024 | 15.76M |
| April 16, 2024 | 16.49M |
| April 15, 2024 | 17.18M |
| April 12, 2024 | 17.54M |
| April 11, 2024 | 17.65M |
| April 10, 2024 | 18.60M |
| April 09, 2024 | 17.98M |
| April 08, 2024 | 18.21M |
| April 05, 2024 | 18.45M |
| April 04, 2024 | 18.58M |
| April 03, 2024 | 18.89M |
| April 02, 2024 | 18.88M |
| Date | Value |
|---|---|
| April 01, 2024 | 19.22M |
| March 28, 2024 | 19.30M |
| March 27, 2024 | 19.96M |
| March 26, 2024 | 18.43M |
| March 25, 2024 | 17.97M |
| March 22, 2024 | 18.15M |
| March 21, 2024 | 17.92M |
| March 20, 2024 | 18.71M |
| March 19, 2024 | 20.11M |
| March 18, 2024 | 23.77M |
| March 15, 2024 | 24.86M |
| March 14, 2024 | 25.58M |
| March 13, 2024 | 25.86M |
| March 12, 2024 | 26.68M |
| March 11, 2024 | 27.50M |
| March 08, 2024 | 27.50M |
| March 07, 2024 | 27.09M |
| March 06, 2024 | 26.68M |
| March 05, 2024 | 25.44M |
| March 04, 2024 | 27.63M |
| March 01, 2024 | 28.18M |
| February 29, 2024 | 28.86M |
| February 28, 2024 | 27.09M |
| February 27, 2024 | 24.76M |
| February 26, 2024 | 24.49M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
4.091M
Minimum
Nov 13 2019
463.49M
Maximum
Apr 28 2021
84.37M
Average
48.14M
Median
May 07 2019
Enterprise Value Benchmarks
| 180 Life Sciences Corp | 0.673M |
| Acurx Pharmaceuticals Inc | 25.62M |
| NovaBay Pharmaceuticals Inc | 2.696M |
| Palatin Technologies Inc | 22.79M |
| iBio Inc | 16.80M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.453M |
| Total Expenses (Quarterly) | 8.011M |
| EPS Diluted (Quarterly) | 0.07 |
| Earnings Yield | -4.73K% |
| Normalized Earnings Yield | -6525.22 |